Table 2.

Ocular signs and symptoms: treatment difference in means at onset and 24 hours post-CAC

Secondary endpoints	Difference in means between olopatadine HCl 0.77% versus vehicle and olopatadine 0.2% at onset of action			Difference in means between olopatadine HCl 0.77% versus vehicle and olopatadine 0.2% at 24-hour duration of action
	7 minutes	15 minutes	20 minutes	7 minutes	15 minutes	20 minutes
Ciliary rednessa
Vehicle	−1.01*	−0.91*	−0.87*	−0.51*	−0.41*	−0.30**
Olopatadine 0.2%	−0.36*	−0.50*	−0.49*	−0.24**	−0.28**	−0.21**
Episcleral rednessa
Vehicle	−0.94*	−0.78*	−0.75*	−0.39*	−0.35**	−0.27**
Olopatadine 0.2%	−0.38*	−0.46*	−0.47*	−0.26**	−0.25**	−0.20**
Chemosisb
Vehicle	−0.42*	−0.49*	−0.49*	−0.36*	−0.44*	−0.45*
Olopatadine 0.2%	−0.06	−0.18**	−0.18**	−0.07	−0.14	−0.12
Eyelid swellingc
Vehicle	−0.50*	−0.40*	−0.30*	−0.50*	−0.40**	−0.30**
Olopatadine 0.2%	−0.10	−0.10	−0.10	−0.20**	−0.10	−0.10
Tearingd
Vehicle	−0.50*	−0.40*	−0.30†	−0.50*	−0.30**	−0.20
Olopatadine 0.2%	0	−0.10	−0.10	−0.10	−0.10	−0.10

Notes:

^aCiliary and episcleral redness each were assessed on a 0–4 scale by 0.5-unit increments: 0= none and 4= extremely severe;

^bchemosis was assessed on a 0–4 scale by 0.5-unit increments: 0= none and 4= severe;

^ceyelid swelling was assessed on a 0–3 scale with 1-unit increments: 0= none and 3= severe; and

^dtearing was assessed on a 0–4 scale by 1-unit increments: 0= none and 4= very severe.

^*P<0.0001 overall and at all other time points versus vehicle;

^**P<0.05 overall and at all time points versus olopatadine 0.2%.

Abbreviation: CAC, conjunctival allergen challenge.